10 minutes | Jun 28th 2018

155 - cannabidiol of lennoxgastault syndrome; clearance of Access hsTnI assay; FRESCA CPAP system; FDA meeting announcement for Nutrition Innovation Strategy

June 28, 2018 Please subscribe, rate and review if you like this podcast. Thank you! The podcast website is http://newfdaapprovals.com 0.33 FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm611046.htm https://www.prnewswire.com/news-releases/first-prescription-formulation-of-cannabidiol-cbd-approved-for-lennox-gastaut-syndrome-300672005.html  2:43 Beckman Coulter Diagnostics Receives U.S. FDA 510(k) Clearance for High- sensitivity Access hsTnI Assay https://www.prnewswire.com/news-releases/beckman-coulter-diagnostics-receives-us-fda-510k-clearance-for-high--sensitivity-access-hstni-assay-300673012.html 5:20 FDA Authorizes FRESCA Medical To Market New Positive Airway Pressure Delivery System To Treat Sleep Apnea https://www.prnewswire.com/news-releases/fda-authorizes-fresca-medical-to-market-new-positive-airway-pressure-delivery-system-to-treat-sleep-apnea-300671067.html  6:39 Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s new steps to advance health through improvements in nutrition under the agency’s Nutrition Innovation Strategy https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm611784.htm Brought to you by Nascent Medical. For assistance with medical writing, please email info@nascentmc.com. Music credit: freemusicarchive.org/music/MindsEye/Yellow_Taxi/
Play Next